A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Recruiting

Phase 1

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamA Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Sponsor:

Incyte Corporation

Code:

NCT06213831

Conditions

Prurigo Nodularis

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib Cream 1.5%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2025-03-25.